Developing Breakthrough Drugs for Heart Failure: Lessons Learned From the Cystic Fibrosis Experience.
Publication
, Journal Article
O'Connor, CM
Published in: JACC Heart Fail
January 2017
Duke Scholars
Published In
JACC Heart Fail
DOI
EISSN
2213-1787
Publication Date
January 2017
Volume
5
Issue
1
Start / End Page
71 / 72
Location
United States
Related Subject Headings
- United States
- Humans
- Heart Failure
- Drug Approval
- Disease Management
- Cystic Fibrosis
- Cardiovascular Agents
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
O’Connor, C. M. (2017). Developing Breakthrough Drugs for Heart Failure: Lessons Learned From the Cystic Fibrosis Experience. JACC Heart Fail, 5(1), 71–72. https://doi.org/10.1016/j.jchf.2016.11.008
O’Connor, Christopher M. “Developing Breakthrough Drugs for Heart Failure: Lessons Learned From the Cystic Fibrosis Experience.” JACC Heart Fail 5, no. 1 (January 2017): 71–72. https://doi.org/10.1016/j.jchf.2016.11.008.
O’Connor CM. Developing Breakthrough Drugs for Heart Failure: Lessons Learned From the Cystic Fibrosis Experience. JACC Heart Fail. 2017 Jan;5(1):71–2.
O’Connor, Christopher M. “Developing Breakthrough Drugs for Heart Failure: Lessons Learned From the Cystic Fibrosis Experience.” JACC Heart Fail, vol. 5, no. 1, Jan. 2017, pp. 71–72. Pubmed, doi:10.1016/j.jchf.2016.11.008.
O’Connor CM. Developing Breakthrough Drugs for Heart Failure: Lessons Learned From the Cystic Fibrosis Experience. JACC Heart Fail. 2017 Jan;5(1):71–72.
Published In
JACC Heart Fail
DOI
EISSN
2213-1787
Publication Date
January 2017
Volume
5
Issue
1
Start / End Page
71 / 72
Location
United States
Related Subject Headings
- United States
- Humans
- Heart Failure
- Drug Approval
- Disease Management
- Cystic Fibrosis
- Cardiovascular Agents
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology